<DOC>
	<DOC>NCT01253564</DOC>
	<brief_summary>This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.</brief_summary>
	<brief_title>A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Metastatic melanoma (Stage IV, American Joint Committee on Cancer) with BRAF mutation (cobas 4800 BRAF V600 Mutation Test) Brain metastases for which surgical resection is not a treatment option Patients must have failed at least one previous treatment for brain metastases Requiring corticosteroids for symptom control Eastern Cooperative Oncology Group (ECOG) performance status 02 Increasing corticosteroid dose during the 7 days prior to study entry Previous malignancy within the past 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma insitu of the cervix Concurrent administration of any anticancer therapies other than those administered in the study Clinically significant cardiovascular disease or event within the 6 months prior to first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>